Sanofi (SNY) Convertible Debt (2013 - 2021)

Sanofi (SNY) posted Convertible Debt of $24.4 billion for Q2 2021, down 9.71% sequentially from $27.0 billion in Q4 2020.

Sanofi (SNY) Convertible Debt (2013 - 2021) Analysis & Trends

Sanofi (SNY) has 2 years of Convertible Debt data on file, last reported at $24.4 billion in Q2 2021.

Quarterly Convertible Debt changed N/A year-over-year to $24.4 billion in Q2 2021, while the trailing twelve-month figure through Jun 2021 was $24.4 billion (changed N/A YoY) and the FY2020 annual result came in at $25.8 billion, changed N/A from the prior year.
Convertible Debt slipped to $24.4 billion in Q2 2021 per SNY's latest filing, from $27.0 billion in the prior quarter.
The five-year high for Convertible Debt was $27.0 billion in Q4 2020, with the low at $24.4 billion in Q2 2021.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Eli Lilly	1,066.16 Bn	1,060.88 Bn	16.22 Bn
2	Johnson & Johnson	611.69 Bn	589.64 Bn	15.96 Bn
3	AbbVie	444.34 Bn	434.99 Bn	10.78 Bn
4	Astrazeneca	284.94 Bn	277.05 Bn	12.61 Bn
5	Merck	224.23 Bn	218.58 Bn	12.09 Bn
6	Amgen	195.12 Bn	183.08 Bn	5.87 Bn
7	Gilead Sciences	156.45 Bn	148.73 Bn	5.52 Bn
8	Pfizer	136.01 Bn	123.24 Bn	-1.21 Bn
9	Novartis Ag	113.45 Bn	113.67 Bn	-
10	Sanofi	-	-	9.49 Bn

Download Data